| Literature DB >> 27430220 |
Shruti Menon1, Scott H Stansfield1, Benignus Logan2, Jane S Hocking3, Peter Timms4, Luk Rombauts5, John A Allan6,7, Wilhelmina M Huston8,6,1.
Abstract
Chlamydia trachomatis results in tubal factor infertility in some women. Diagnosis of this tubal infertility is difficult and typically involves laparoscopy or hysterosalpingography to detect the tubal blockages. Numerous serological tests have been developed; however, they are presently not used for diagnosis without subsequent surgical investigation during the infertility investigation. This study aimed to develop a highly specific serological assay for chlamydial tubal factor infertility in women that could be used to recommend direct progression to invitro fertilization (IVF) treatment for women who are positive. Women were recruited from a variety of settings including women seeking fertility treatment, sexual health and general practitioner (GP) consultations or antenatal care (n=259). The serological assay was developed using sera from a large group of women by using infertile microimmunofluorescence (MIF)-positive women with tubal damage as the positives compared to infertile or acute infection and/or fertile controls (negatives). The new multi-peptide ELISA was highly specific for the detection of tubal factor infertility (P=0.011) compared to another ELISA (P=0.022) and MIF (P=0.099). The sensitivity of the assay should be improved before clinical utility. Potentially, a two-step testing protocol could be used during the initial infertility investigation, where MIF followed by a highly specific ELISA could be used to recommend direct progression to IVF for women who are positive.Entities:
Keywords: ELISA; chlamydia; peptide; serology; tubal factor
Year: 2016 PMID: 27430220 DOI: 10.1099/jmm.0.000311
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472